title: Effect of desipramine and citalopram treatment on forced swimming test-induced changes in cocaine- and amphetamine-regulated transcript (CART) immunoreactivity in mice.
abstract: Recent study demonstrates antidepressant-like effect of cocaine- and amphetamine-regulated transcript (CART) in the forced swimming test (FST), but less is known about whether antidepressant treatments alter levels of CART immunoreactivity (CART-IR) in the FST. To explore this possibility, we assessed the treatment effects of desipramine and citalopram, which inhibit the reuptake of norepinephrine and serotonin into the presynaptic terminals, respectively, on changes in levels of CART-IR before and after the test swim in mouse brain. Levels of CART-IR in the nucleus accumbens shell (AcbSh), dorsal bed nucleus of the stria terminalis (dBNST), and hypothalamic paraventricular nucleus (PVN) were significantly increased before the test swim by desipramine and citalopram treatments. This increase in CART-IR in the AcbSh, dBNST, and PVN before the test swim remained elevated by desipramine treatment after the test swim, but this increase in these brain areas returned to near control levels after test swim by citalopram treatment. Citalopram, but not desipramine, treatment increased levels of CART-IR in the central nucleus of the amygdala (CeA) and the locus ceruleus (LC) before the test swim, and this increase was returned to control levels after the test swim in the CeA, but not in the LC. These results suggest common and distinct regulation of CART by desipramine and citalopram treatments in the FST and raise the possibility that CART in the AcbSh, dBNST, and CeA may be involved in antidepressant-like effect in the FST.
authors.affiliation: Department of Pharmacology, Korea University College of Medicine, 126-1, 5-ga, Anam-dong, Seongbuk-gu, Seoul, 136-705, Republic of Korea.
authors.forename: Sung
authors.initials: S
authors.lastname: Chung
authors.forename: Hee Jeong
authors.initials: HJ
authors.lastname: Kim
authors.forename: Hyun Ju
authors.initials: HJ
authors.lastname: Kim
authors.forename: Sun Hye
authors.initials: SH
authors.lastname: Choi
authors.forename: Jin Wook
authors.initials: JW
authors.lastname: Kim
authors.forename: Jeong Min
authors.initials: JM
authors.lastname: Kim
authors.forename: Kyung Ho
authors.initials: KH
authors.lastname: Shin
mesh_terms: D000679:Amygdala / Q000187:drug effects; D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology; D015283:Citalopram / Q000494:pharmacology*; D003891:Desipramine / Q000494:pharmacology*; D008125:Locus Coeruleus / Q000378:metabolism; D008297:Male; D008813:Mice, Inbred ICR; D009419:Nerve Tissue Proteins / Q000096:biosynthesis*; D013550:Swimming / Q000523:psychology*; D000098882:Cocaine- and Amphetamine-Regulated Transcript Protein
chemical_list: D000928:Antidepressive Agents; D009419:Nerve Tissue Proteins; D000098882:Cocaine- and Amphetamine-Regulated Transcript Protein; D015283:Citalopram; D003891:Desipramine
references.citation: Nat Rev Neurosci. 2008 Oct;9(10):747-58
references.pmid: 18802445
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2010 Aug;382(2):151-8
references.pmid: 20526847
references.citation: Neuropeptides. 2006 Jun;40(3):185-93
references.pmid: 16644010
references.citation: Biol Psychiatry. 2000 May 1;47(9):818-29
references.pmid: 10812041
references.citation: Proc Natl Acad Sci U S A. 2003 May 13;100(10):6227-32
references.pmid: 12732720
references.citation: Eur J Pharmacol. 2010 Nov 25;647(1-3):110-6
references.pmid: 20826136
references.citation: Neurosci Res. 2009 Oct;65(2):210-3
references.pmid: 19577595
references.citation: Mol Pharmacol. 2009 Mar;75(3):704-12
references.pmid: 19106229
references.citation: Behav Pharmacol. 1997 Nov;8(6-7):523-32
references.pmid: 9832966
references.citation: Neuropsychopharmacology. 1988 Dec;1(4):287-95
references.pmid: 2908021
references.citation: Synapse. 1999 Sep 1;33(3):163-71
references.pmid: 10420164
references.citation: J Neurosci. 1999 May 15;19(10):RC5
references.pmid: 10234051
references.citation: Curr Neuropharmacol. 2011 Mar;9(1):12-6
references.pmid: 21886553
references.citation: Life Sci. 2007 Mar 27;80(16):1539-43
references.pmid: 17306836
references.citation: Neuropsychopharmacology. 2009 Apr;34(5):1288-300
references.pmid: 19005467
references.citation: Neurosci Biobehav Rev. 2005;29(4-5):547-69
references.pmid: 15893822
references.citation: J Neuroendocrinol. 2007 Jun;19(6):461-73
references.pmid: 17504440
references.citation: Neuropharmacology. 1986 Apr;25(4):367-84
references.pmid: 2872608
references.citation: J Pharmacol Exp Ther. 2003 Dec;307(3):1038-44
references.pmid: 14551286
references.citation: Depress Res Treat. 2011;2011:762139
references.pmid: 21785720
references.citation: Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18620-5
references.pmid: 16352709
references.citation: Synapse. 2011 Jan;65(1):1-7
references.pmid: 20506412
references.citation: Neuropsychopharmacology. 2006 Nov;31(11):2424-32
references.pmid: 16554743
references.citation: J Clin Psychiatry. 2000;61 Suppl 1:5-12
references.pmid: 10703757
references.citation: Pharmacol Biochem Behav. 2011 Jun;98(4):544-51
references.pmid: 21397628
references.citation: Peptides. 2006 Aug;27(8):1942-8
references.pmid: 16697078
references.citation: Brain Res. 2001 Mar 2;893(1-2):186-94
references.pmid: 11223006
references.citation: Psychopharmacology (Berl). 1995 Sep;121(1):66-72
references.pmid: 8539342
references.citation: Nature. 1977 Apr 21;266(5604):730-2
references.pmid: 559941
references.citation: Brain Res. 2012 Oct 15;1479:62-71
references.pmid: 22960117
references.citation: Behav Brain Funct. 2010 Jun 01;6:30
references.pmid: 20515458
references.citation: J Pharmacol Exp Ther. 1999 May;289(2):926-35
references.pmid: 10215672
references.citation: Synapse. 2007 Jul;61(7):561-8
references.pmid: 17447258
references.citation: J Neurosci. 2001 Sep 15;21(18):7397-403
references.pmid: 11549750
references.citation: Eur J Pharmacol. 2004 Jun 28;494(2-3):179-82
references.pmid: 15212972
references.citation: Int J Neuropsychopharmacol. 2013 May;16(4):813-23
references.pmid: 22695046
references.citation: Neurosci Lett. 2007 May 7;417(3):303-7
references.pmid: 17346884
references.citation: Peptides. 2011 Feb;32(2):317-26
references.pmid: 21167239
references.citation: Endocrinology. 2000 Feb;141(2):794-801
references.pmid: 10650962
references.citation: Brain Res. 2001 Oct 26;917(1):15-20
references.pmid: 11602226
references.citation: Ann N Y Acad Sci. 1993 Oct 29;697:173-88
references.pmid: 7903030
references.citation: J Neuroendocrinol. 1999 Jun;11(6):465-71
references.pmid: 10336728
references.citation: Physiol Behav. 2007 Sep 10;92(1-2):218-25
references.pmid: 17631364
references.citation: Brain Res. 2009 Jan 28;1251:42-52
references.pmid: 19046951
references.citation: Eur J Pharmacol. 1987 Aug 11;140(2):239-44
references.pmid: 2822440
references.citation: J Comp Neurol. 1998 Feb 2;391(1):115-32
references.pmid: 9527537
references.citation: Curr Neuropharmacol. 2006 Oct;4(4):277-91
references.pmid: 18654637
references.citation: Brain Res. 2004 Mar 5;999(2):181-92
references.pmid: 14759497
references.citation: J Pharmacol Exp Ther. 2001 Oct;299(1):268-76
references.pmid: 11561089
references.citation: Eur J Pharmacol. 2003 Mar 7;464(1):49-54
references.pmid: 12600694
references.citation: J Neurochem. 2005 Oct;95(2):484-98
references.pmid: 16190871
references.citation: J Neurosci. 2004 Feb 25;24(8):1967-75
references.pmid: 14985439